To understand the mechanism HU treatment, we employed RNA sequencing (RNA-Seq) and mass spectrometry (MS) to systematically contrast the gene expression profiling and proteome of MLL-AF9 and non-MLL AML cells. This evidence concerns the gene MLLT3 and acute myeloid leukemia.